A jointly-produced filing between Apple and Epic in its ongoing “Fortnite” courtroom saga reveals issues with discovery on both sides ahead of a case management conference, with each claiming the other isn’t providing the required documentation.
In the Joint Case Management Statement filed on Monday, in advance of the case management conference scheduled for October 19, Epic and Apple both have issues with how the other company is handling the discovery portion of the lawsuits. Each company accuses the other of being uncooperative in different ways.
In Epic’s portion of the statement, it accuses Apple of failing to provide all of the documentation it needs, namely that Apple’s list of custodians that documents are supplied about does not include two prominent figures in Apple’s history. Of the six people listed, Epic spotted that none of them are co-founder and late CEO Steve Jobs and current CEO Tim Cook.
Furthermore, Epic also claims Apple “repeatedly relied” on the two men during the two previous motion hearings. However, Apple countered by saying it didn’t rely on them, rather that it mentioned the two twice, referencing Tim Cook’s statement to the US House of Representatives Judiciary Committee and “an AppleInsider article quoting Steve Jobs.”
Apple also claims it has already provided Epic “with the 3.6 million documents” produced by Apple in its developer class action and consumer class action suits. Epic believes these documents should have been provided sooner.
On Epic’s side, it has already made “an initial production of more than 16,000 pages form the files of Timothy Sweeney,” the CEO of Epic. Apple counters by claiming Epic may have “cherry-picked” the documents that may “omit a significant amount of relevant materials.”
Apple also claims Epic received a third-party discovery request before it formed its lawsuit
Worldwide Drug Modeling Software Industry to 2027 – Increasing Adoption of Modelling Tools in Drug Discovery is Driving Growth
DUBLIN, Oct. 2, 2020 /PRNewswire/ — The “Drug Modeling Software Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product type; Application, and Geography” report has been added to ResearchAndMarkets.com’s offering.
According to this report the global drug modeling software biopharmaceutical market is expected to reach US$ 11,299.85 million by 2027 from US$ 6,205.22 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The report highlights the trends prevalent in the global drug modeling software market, and the drivers and deterrents pertaining to its growth.
Based on product type, the drug modeling software market is segmented into database, software, and others. In terms of product type, the software segment held the highest share of the drug modeling software market in 2019 and is estimated to register the highest CAGR of 8.4% in the market during the forecast period. The growth of the market is attributed to the growing demand for effective therapeutics and increasing number of drug discovery efforts of various biologics across a wide range of therapeutics. Additionally, strategic activities by service providers such as collaborations, product advancement, and product launch in order to expedite drug discovery timeline are further accelerating the growth of the market.
The market growth is also attributed to a few key factors such as increasing adoption of in-silico modeling tools in drug discovery, and rising economic burden of drug discovery. However, less adoption in emerging countries is expected to hamper the growth of the market up to certain extent during the forecast period.
Crown Bioscience Inc.; Chemical Computing Group Ulc; Nimbus Therapeutics; Schrdinger, Inc.; Dassault Systmes; Genedata Ag; Biognos Ab; Compugen Ltd; Acellera ltd.; and Leadscope, Inc plc are among the prominent players operating in the drug modeling software market. The market players